PR Newswire Clinical TrialsOriginal article
Raymond Douglas, MD, PhD, Unveils Research on Six-Week Teprotumumab Dosing to Help Protect Hearing
ConferenceTeprotumumabPositive
AI Analysis
Summary
Dr. Raymond Douglas presented research on a six-week teprotumumab dosing regimen intended to help protect hearing in thyroid eye disease patients at the American Society of Ophthalmic Plastic Surgeons conference. The presentation highlights ongoing research on the FDA-approved TED treatment.
Outcome Details
Research presentation on six-week teprotumumab dosing regimen for hearing protection
Importance:3/10
Sentiment:
0.30
Thyroid Eye DiseaseTeprotumumabConference PresentationDosing ResearchHearing Protection
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on October 12, 2026 2:42 PM